共有 50 笔近期内部人交易记录记录，涉及 Brainstorm Cell Therapeutics Inc. (BCLI), 包括 44 笔买入 和 1 笔卖出. 内部人买入总额为 $575.32K 内部人卖出总额为 $22.07K.
近期活跃的重要内部人包括 Hartounian Hartoun, Frenkel Jacob A, Arbel Irit. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — BCLI
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2025-01-01 |
Hartounian Hartoun |
EVP, Chief Operating Officer |
限制性股票授予 (RSU) |
50,000 |
- |
- |
52,000 |
| 2025-01-01 |
Frenkel Jacob A |
Director |
限制性股票授予 (RSU) |
40,000 |
- |
- |
43,777 |
| 2025-01-01 |
Arbel Irit |
Director |
限制性股票授予 (RSU) |
30,666 |
- |
- |
41,054 |
| 2025-01-01 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
120,000 |
- |
- |
200,960 |
| 2025-01-01 |
Yablonka Uri |
EVP & Chief Business Officer |
限制性股票授予 (RSU) |
40,000 |
- |
- |
48,464 |
| 2025-01-01 |
Patlis Alla |
See Remarks |
限制性股票授予 (RSU) |
40,000 |
- |
- |
44,349 |
| 2025-01-01 |
Polverino Anthony J. |
Director |
限制性股票授予 (RSU) |
24,000 |
- |
- |
25,730 |
| 2025-01-01 |
Lindborg Stacy |
Director |
限制性股票授予 (RSU) |
20,000 |
- |
- |
48,229 |
| 2025-01-01 |
Bairu Menghisteab |
Director |
限制性股票授予 (RSU) |
24,000 |
- |
- |
24,000 |
| 2025-01-01 |
Naor Nir |
Director |
限制性股票授予 (RSU) |
30,666 |
- |
- |
31,465 |
| 2025-01-01 |
Dagher Ibrahim B. |
Chief Medical Officer |
限制性股票授予 (RSU) |
50,000 |
- |
- |
66,849 |
| 2024-10-01 |
Lebovits Chaim |
President & CEO |
知情买入 |
1,836 |
$3.43 |
$6.29K |
80,960 |
| 2024-09-30 |
Lebovits Chaim |
President & CEO |
知情买入 |
22,000 |
$0.23 |
$5.02K |
1,186,865 |
| 2024-07-19 |
Dagher Ibrahim B. |
Chief Medical Officer |
知情卖出 |
63,000 |
$0.35 |
$22.07K |
- |
| 2024-06-24 |
Hartounian Hartoun |
Officer |
未知 |
- |
- |
- |
- |
| 2024-06-24 |
Hartounian Hartoun |
EVP, Chief Operating Officer |
限制性股票授予 (RSU) |
30,000 |
- |
- |
30,000 |
| 2024-05-28 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
15,000 |
$0.52 |
$7.77K |
1,164,865 |
| 2024-05-28 |
Lebovits Chaim |
President & CEO |
知情买入 |
15,000 |
$0.52 |
$7.77K |
1,164,865 |
| 2024-05-22 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
25,000 |
$0.64 |
$16K |
1,149,865 |
| 2024-05-22 |
Lebovits Chaim |
President & CEO |
知情买入 |
25,000 |
$0.64 |
$16K |
1,149,865 |
| 2024-05-21 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
25,000 |
$0.58 |
$14.48K |
1,124,865 |
| 2024-05-21 |
Lebovits Chaim |
President & CEO |
知情买入 |
25,000 |
$0.58 |
$14.48K |
1,124,865 |
| 2024-05-13 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
10,000 |
$0.49 |
$4.9K |
1,099,865 |
| 2024-05-13 |
Lebovits Chaim |
President & CEO |
知情买入 |
10,000 |
$0.49 |
$4.9K |
1,099,865 |
| 2024-05-11 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
10,000 |
$0.47 |
$4.67K |
1,089,865 |
| 2024-05-11 |
Lebovits Chaim |
President & CEO |
知情买入 |
10,000 |
$0.47 |
$4.67K |
1,089,865 |
| 2024-05-10 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
20,000 |
$0.47 |
$9.3K |
1,079,865 |
| 2024-05-10 |
Lebovits Chaim |
President & CEO |
知情买入 |
20,000 |
$0.47 |
$9.3K |
1,079,865 |
| 2024-05-07 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
66,300 |
$0.37 |
$24.82K |
1,059,865 |
| 2024-05-07 |
Lebovits Chaim |
President & CEO |
知情买入 |
66,300 |
$0.37 |
$24.82K |
1,059,865 |
| 2024-05-06 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
135,000 |
$0.38 |
$50.67K |
993,565 |
| 2024-05-06 |
Lebovits Chaim |
President & CEO |
知情买入 |
135,000 |
$0.38 |
$50.67K |
993,565 |
| 2024-04-19 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
15,000 |
$0.52 |
$7.8K |
858,565 |
| 2024-04-19 |
Lebovits Chaim |
President & CEO |
知情买入 |
15,000 |
$0.52 |
$7.8K |
858,565 |
| 2024-04-18 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
115,072 |
$0.53 |
$60.47K |
843,565 |
| 2024-04-18 |
Lebovits Chaim |
President & CEO |
知情买入 |
115,072 |
$0.53 |
$60.47K |
843,565 |
| 2024-04-17 |
Dagher Ibrahim B. |
Chief Medical Officer |
未知 |
80,000 |
$1.73 |
$138.4K |
- |
| 2024-04-17 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
130,000 |
$0.55 |
$70.94K |
728,493 |
| 2024-04-17 |
Dagher Ibrahim B. |
Chief Medical Officer |
未知 |
- |
- |
- |
30,000 |
| 2024-04-17 |
Lebovits Chaim |
President & CEO |
知情买入 |
130,000 |
$0.55 |
$70.94K |
728,493 |
| 2024-03-11 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
305,198 |
- |
- |
598,493 |
| 2024-03-11 |
Yablonka Uri |
EVP & Chief Business Officer |
限制性股票授予 (RSU) |
109,426 |
- |
- |
126,969 |
| 2024-03-11 |
Patlis Alla |
See Remarks |
限制性股票授予 (RSU) |
65,246 |
- |
- |
65,246 |
| 2024-03-11 |
Lindborg Stacy |
Co-chief Executive Officer |
限制性股票授予 (RSU) |
241,935 |
- |
- |
423,435 |
| 2023-09-01 |
Lindborg Stacy |
Co-chief Executive Officer |
知情买入 |
11,500 |
$1.77 |
$20.4K |
181,500 |
| 2023-08-02 |
Lebovits Chaim |
President & CEO |
限制性股票授予 (RSU) |
31,185 |
- |
- |
293,295 |
| 2023-08-02 |
Lindborg Stacy |
Co-chief Executive Officer |
限制性股票授予 (RSU) |
35,000 |
- |
- |
170,000 |
| 2023-06-19 |
Naor Nir |
Director |
未知 |
- |
- |
- |
- |
| 2023-06-19 |
Naor Nir |
Director |
限制性股票授予 (RSU) |
11,999 |
- |
- |
11,999 |
| 2023-05-01 |
Taylor Kirk |
Officer |
未知 |
- |
- |
- |
- |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
